Court Favors Boehringer In Third Pradaxa Bellwether Trial
Court Favors Boehringer In Third Pradaxa Bellwether Trial
Introduction
A Hartford Superior Court ruled in favor of Boehringer Ingelheim Pharmaceuticals in the third bellwether trial involving claims by a man who suffered bleeding due to the alleged use of blood thinner medication Pradaxa.
The trial for claims brought by the plaintiff in 2016 concluded after a three-week deliberation, and it is the third straight win for Boehringer. The first two trials held in March 2018 and May 2018 also ended in a defense verdict. The next bellwether trial involving claims of health hazards of Pradaxa will begin in February 2019.
Pradaxa was initially approved by the U.S. FDA to be used as a blood thinner, but reports suggest it causes serious injuries and gastrointestinal bleeding, heart attack, stroke, brain hemorrhage, kidney bleeding, and death. Judge Herndon, who overlooked Pradaxa class action lawsuits, recommended a shutdown of the multidistrict litigation (MDL No. 2385) in December 2017 after dismissing pending cases in the docket.
Comments
Latest News
Attorneys Seek Reconsideration of Talc MDL Daubert Ruling
Categories: General
Plaintiffs’ attorneys are urging the U.S. District Judge overseeing the talcum powder lawsuit MDL to reconsider a recent decision for a second round…
Philips resolves DreamStation suits for $1.1B
Categories: Settlements
Dutch medical technology company Philips has finalized a $1.1 billion settlement in the United States to address lawsuits concerning faulty…
FDA OKs Generic OTC Naloxone Spray Approved by FDA
Categories: FDA Related
The FDA has granted approval for Amneal Pharmaceuticals to release a generic 4 mg naloxone hydrochloride nasal spray for over-the-counter (OTC) use, an announcement made in a press release.
…